Triple assessment is the standard UK approach to investigating a breast lump or other new symptom, combining three components in a single visit: clinical examination, imaging (ultrasound and/or mammogram), and tissue sampling (core biopsy) where indicated.
The three components — examination, imaging, and biopsy — are each useful on their own, but their power comes from being done together. A diagnosis that all three agree on is highly reliable; where they disagree, the case is reviewed at MDT and further work-up is arranged. Triple assessment is what the one-stop breast clinic is built around.
Orientation Why you might be reading about this
You have probably been referred for a triple assessment, or one was done at your one-stop clinic visit. Patients often arrive at the appointment without knowing what the term means, and leave having had all three parts done in around 90 minutes. This page explains what triple assessment is, why all three components matter, and what the result tells you.
Related terms: Breast lump · Mammogram · Breast ultrasound · Core biopsy · Breast cyst
The components The three components
Each part of triple assessment is a distinct investigation, and each is given a separate score by the clinician performing it. The scores use a simple system: P for clinical examination, M for mammogram, U for ultrasound, and B for biopsy, each followed by a number from 1 (normal) to 5 (highly suspicious of cancer)2.
1. Clinical examination (P)
A breast specialist examines both breasts and the lymph nodes in the armpit, asking about the symptom and how it has changed over time. Examination findings — particularly the size, mobility, and texture of any lump, and any associated skin or nipple change — are graded:
- P1 — normal.
- P2 — benign.
- P3 — uncertain / probably benign.
- P4 — suspicious of cancer.
- P5 — clinically malignant.
2. Imaging (M and U)
Imaging in breast clinics uses two complementary tests:
- Ultrasound (U) — used in patients of any age, particularly under 40 where breast tissue is denser4. Ultrasound is good at distinguishing solid lumps from fluid-filled cysts and at imaging dense tissue.
- Mammogram (M) — used in patients over about 40, and added to ultrasound in younger patients where the picture is unclear4. Mammograms are good at picking up microcalcifications and the small early cancers in less dense tissue.
Each is scored from 1 (normal) to 5 (highly suspicious).
3. Tissue sampling — core biopsy (B)
If the imaging shows anything that warrants a tissue diagnosis, a core biopsy is performed under image guidance — usually at the same visit, under local anaesthetic. Biopsy results are scored from 1 (insufficient material) to 5 (malignant), with B3 (uncertain), B4 (suspicious), B2 (benign), and B5 (malignant) being the most commonly seen results.
A typical fully clear biopsy result reads “B2 — fibroadenoma” or similar.
Putting it together Putting the three together
The strength of triple assessment is in agreement — when all three components point to the same diagnosis, the result is highly reliable, and the patient can be confidently reassured (or referred onwards for treatment, depending on what the diagnosis is)3.
When the three components disagree — for example, an imaging finding that looks suspicious but a benign biopsy result — the case is reviewed at the multidisciplinary team meeting2. The team considers whether to repeat the biopsy, take a larger sample, perform additional imaging, or proceed to a surgical excision for confirmation. Discordance between the components is the key reason triple assessment is more sensitive than any single test alone3.
Why one visit Why a one-stop visit
In modern UK breast practice, all three components are usually performed in a single visit — a “one-stop clinic”. Practical advantages:
- The radiologist is in the room during the imaging, so any biopsy that is needed can be done immediately under image guidance, rather than at a separate appointment.
- Imaging results are available the same day, so the patient leaves with the diagnostic picture clear (apart from the biopsy, where one was performed — those results follow within a few working days).
- The first appointment usually answers the question — most one-stop visits give a confident benign or malignant diagnosis at the visit itself or within a few working days.
For more on the one-stop pathway, see the one-stop breast clinic page.
Limitations When triple assessment is NOT used
Some presentations do not need full triple assessment:
- Asymptomatic patients on routine screening are managed through the screening pathway (mammography alone in most cases).
- Patients with classic features of a hormonal change — for example, cyclical pain alone, with no lump and a normal examination — can sometimes be reassured without imaging. (When in doubt, imaging is usually still done.)
- Follow-up of known benign findings is done with appropriate-interval imaging rather than full triple assessment each time.
For a new symptom, however, full triple assessment is the default.
At consultation What to discuss at consultation
The triple assessment process itself is usually self-explanatory once you arrive at the clinic, but it is worth knowing what the result means:
- What were the three component scores (e.g. P2 / U2 / B2 = consistent with benign), and do they agree?
- If a biopsy was needed, when will the result be available, and how will it be communicated?
- If anything is uncertain, what is the next step — repeat biopsy, MRI, MDT review, or surgical excision?
If the first finding was a lump, the breast lump page describes how that pathway is assessed.
Resources Further reading
- NICE NG12 — Suspected cancer: recognition and referral — UK clinical guidance for triple assessment and the wider referral pathway.
- NHS — Breast cancer in women: Diagnosis — patient guide to the components of triple assessment.
- Breast Cancer Now — Screening, tests and scans — patient-focused guide.
- Breastory: One-stop breast clinic · Symptoms assessment · Glossary: mammogram · Glossary: breast ultrasound · Glossary: core biopsy